MAPT and Alzheimer disease: As clinical trials have increasingly focused on individuals in the earliest preclinical phases of AD, our results highlight that the selection of Aβ+/Ast+ CU individuals without overt p-tau abnormality may offer a time window very early in the disease process but with an increased risk of AD-related progression.